Company profile
Immuron Ltd
NASDAQ:IMRNBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02316717 | phase2 | completed | 2014-12-01 | 2017-10-30 | Immuron Ltd. | A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis |
| NCT05933525 | phase2 | completed | 2023-05-29 | 2024-07-01 | Immuron Ltd. | Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model. |
| NCT01466894 | phase2 | withdrawn | 2012-12-01 | 2013-12-01 | Immuron Ltd. | Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis |
| NCT03065374 | phase1_2 | terminated | 2017-09-01 | 2019-11-07 | Immuron Ltd. | Treatment for Clostridium-difficile Infection With IMM529 |
FDA applications (0)
No records yet.